Sofgen Pharma S.A. 6-K Filing
Ticker: PRCWF · Form: 6-K · Filed: Dec 5, 2025 · CIK: 1863362
Sentiment: neutral
Filing Stats: 4,623 words · 18 min read · ~15 pages · Grade level 12 · Accepted 2025-12-05 16:05:26
Filing Documents
- ea0268660-6k_sofgen.htm (6-K) — 90KB
- ea026866001ex99-1_sofgen.htm (EX-99.1) — 276KB
- 0001213900-25-118714.txt ( ) — 367KB
financial statements for the financial year ended December 31, 2023
financial statements for the financial year ended December 31, 2023. No vote was required on this item of the agenda. At the Annual General Meeting, the Board presented the report issued by the Company’s independent auditor ( réviseur d’entreprises agréé ), Deloitte Audit, a société à responsabilité limitée existing under the laws of the Grand Duchy of Luxembourg, registered with the Luxembourg Trade and Companies’ Register ( Registre de commerce et des sociétés, Luxembourg ) under number B67895, having its registered office at 20, boulevard de Kockelscheuer, L-1821 Luxembourg, Grand Duchy of Luxembourg, on the 2023 Consolidated Financial Statements (the “ 2023 Auditor Report ”) relating to the financial year ended December 31, 2023. 7. Presentation of the report of the statutory auditor of the Company in respect of the standalone annual accounts for the financial year ended December 31, 2023. No vote was required on this item of the agenda. At the Annual General Meeting, the Board presented the report issued by the Company’s statutory auditor ( commissaire aux comptes ), Mr. Carlos A. Piocuda Russo, on the 2023 Annual Accounts (the “ 2023 Statutory Report ”) relating to the financial year ended December 31, 2023. 8. Presentation and approval of the audited consolidated financial statements for the financial year ended December 31, 2023 prepared in accordance with the International Financial Reporting Standards (IFRS). At the Annual General Meeting, after having reviewed the Form 20-F and the 2023 Auditor Report, the shareholders resolved to approve the audited consolidated financial statements of the Company for the financial year ended December 31, 2023 prepared in accordance with the International Financial Reporting Standards (IFRS) (the “ 2023 Consolidated Financial Statements ”). This resolution was approved by 2,048,453